Literature DB >> 9882388

Gamma interferon is a major suppressive factor produced by activated human peripheral blood lymphocytes that is able to inhibit foamy virus-induced cytopathic effects.

V Falcone1, M Schweizer, A Toniolo, D Neumann-Haefelin, A Meyerhans.   

Abstract

The activation of human peripheral blood lymphocytes by mitogens or by triggering the T-cell receptor with anti-CD3 antibodies leads to the production of a potent soluble inhibitory activity against foamy virus-induced cytopathic effects in vitro. The inhibitory activity acts in a species-specific manner. As a consequence, the isolation of foamy viruses from blood lymphocytes of infected humans is accelerated in a heterologous coculture system. Antibodies against gamma interferon (IFN-gamma) are able to suppress most of the inhibitory activity, suggesting that IFN-gamma is the dominant component.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9882388      PMCID: PMC104007     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Constitutive expression of (2'-5') oligo A synthetase confers resistance to picornavirus infection.

Authors:  J Chebath; P Benech; M Revel; M Vigneron
Journal:  Nature       Date:  1987 Dec 10-16       Impact factor: 49.962

Review 2.  Mutations and A/I hypermutations in measles virus persistent infections.

Authors:  R Cattaneo; M A Billeter
Journal:  Curr Top Microbiol Immunol       Date:  1992       Impact factor: 4.291

Review 3.  Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8+ T cells.

Authors:  J A Levy; C E Mackewicz; E Barker
Journal:  Immunol Today       Date:  1996-05

4.  Induction of avian tumor viruses in normal cells by physical and chemical carcinogens.

Authors:  R A Weiss; R R Friis; E Katz; P K Vogt
Journal:  Virology       Date:  1971-12       Impact factor: 3.616

5.  In vitro studies on interferon-inducing capacity and sensitivity to IFN of human foamy virus.

Authors:  A Sabile; A Rhodes-Feuillette; F Z Jaoui; J Tobaly-Tapiero; M L Giron; J Lasneret; J Périès; M Canivet
Journal:  Res Virol       Date:  1996 Jan-Feb

6.  Simian foamy virus isolated from an accidentally infected human individual.

Authors:  M Schweizer; V Falcone; J Gänge; R Turek; D Neumann-Haefelin
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

7.  Effects of human recombinant alpha and gamma and of highly purified natural beta interferons on simian Spumavirinae prototype (simian foamy virus 1) multiplication in human cells.

Authors:  A Rhodes-Feuillette; J Lasneret; S Paulien; W Ogunkolade; J Periés; M Canivet
Journal:  Res Virol       Date:  1990 Jan-Feb

8.  Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver.

Authors:  L G Guidotti; P Borrow; M V Hobbs; B Matzke; I Gresser; M B Oldstone; F V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

9.  Detection of human C-type "helper" viruses in human leukemic bone marrow with murine sarcoma virus-transformed human and rat non-producer cells.

Authors:  K Nooter; P Bentvelzen; C Zurcher; J Rhim
Journal:  Int J Cancer       Date:  1977-01       Impact factor: 7.396

10.  Restricted replication of lentiviruses. Visna viruses induce a unique interferon during interaction between lymphocytes and infected macrophages.

Authors:  O Narayan; D Sheffer; J E Clements; G Tennekoon
Journal:  J Exp Med       Date:  1985-12-01       Impact factor: 14.307

View more
  12 in total

1.  Basic residues in the foamy virus Gag protein.

Authors:  Daniel Matthes; Tatiana Wiktorowicz; Juliane Zahn; Jochen Bodem; Nicole Stanke; Dirk Lindemann; Axel Rethwilm
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

2.  Expanded tissue targets for foamy virus replication with simian immunodeficiency virus-induced immunosuppression.

Authors:  S M Murray; L J Picker; M K Axthelm; M L Linial
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  Cell-type-specific regulation of the two foamy virus promoters.

Authors:  C D Meiering; C Rubio; C May; M L Linial
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

4.  N-Myc interactor inhibits prototype foamy virus by sequestering viral Tas protein in the cytoplasm.

Authors:  Xiaomei Hu; Wei Yang; Ruikang Liu; Yunqi Geng; Wentao Qiao; Juan Tan
Journal:  J Virol       Date:  2014-04-09       Impact factor: 5.103

5.  IFP35 is involved in the antiviral function of interferon by association with the viral tas transactivator of bovine foamy virus.

Authors:  Juan Tan; Wentao Qiao; Jian Wang; Fengwen Xu; Yue Li; Jun Zhou; Qimin Chen; Yunqi Geng
Journal:  J Virol       Date:  2008-02-27       Impact factor: 5.103

6.  The promyelocytic leukemia protein does not mediate foamy virus latency in vitro.

Authors:  Christopher D Meiering; Maxine L Linial
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

Review 7.  Evolution of foamy viruses: the most ancient of all retroviruses.

Authors:  Axel Rethwilm; Jochen Bodem
Journal:  Viruses       Date:  2013-09-25       Impact factor: 5.048

Review 8.  Origin, evolution and innate immune control of simian foamy viruses in humans.

Authors:  Rejane Rua; Antoine Gessain
Journal:  Curr Opin Virol       Date:  2015-02-17       Impact factor: 7.090

9.  Insights into Innate Sensing of Prototype Foamy Viruses in Myeloid Cells.

Authors:  Maïwenn Bergez; Jakob Weber; Maximilian Riess; Alexander Erdbeer; Janna Seifried; Nicole Stanke; Clara Munz; Veit Hornung; Renate König; Dirk Lindemann
Journal:  Viruses       Date:  2019-11-26       Impact factor: 5.048

10.  Potent neutralizing antibodies in humans infected with zoonotic simian foamy viruses target conserved epitopes located in the dimorphic domain of the surface envelope protein.

Authors:  Caroline Lambert; Mathilde Couteaudier; Julie Gouzil; Léa Richard; Thomas Montange; Edouard Betsem; Réjane Rua; Joelle Tobaly-Tapiero; Dirk Lindemann; Richard Njouom; Augustin Mouinga-Ondémé; Antoine Gessain; Florence Buseyne
Journal:  PLoS Pathog       Date:  2018-10-08       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.